Philips’ investors can ill-afford another jolt to their nerves - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
飞利浦

Philips’ investors can ill-afford another jolt to their nerves

Investors in the Dutch healthcare conglomerate had until this week been enjoying a restorative patch

Some companies, it seems, receive the benefit of the doubt even if their performance is a little ho-hum. They can, for example, highlight weak Chinese demand and get away with a mere share price ripple. Other stocks take a razor-sharp cut on every lump and bump. 

Philips is a case in point. Investors in the Dutch healthcare conglomerate, which makes everything from diagnostic machines to electric shavers, had until this week been enjoying a restorative patch. Legal woes over malfunctioning sleep apnoea machines had been resolved faster and more cheaply than feared, and sales seemed to be heading in the right direction.

But a stumble has undone much of the progress. Philips’ stock has fallen 15 per cent since it released soft third-quarter results on Monday. While Italy’s Agnelli family — who made a big investment in the stock in August 2023 through their public vehicle Exor — is still in the money, this week marks a blow for those who had more recently got behind Philips’ turnaround story.

Investors must be wondering what exactly hit them. The issues Philips highlighted at third-quarter results are hardly unheard of. An anti-corruption drive at Chinese hospitals is slowing procurement of diagnostics machines — a headwind that drove guidance downgrades at rivals Siemens Healthineers and GE Healthcare after second-quarter results, points out Lisa Clive at Bernstein. And while a double-digit fall in personal care sales in China is surprising in its magnitude, the weakness of Chinese consumer demand has been widely flagged across industries.

Meanwhile, results outside China are strong. Operating margins remain healthy despite slower than expected sales. Philips does not look expensive, either. It trades on 15 times next year’s — reduced — earnings expectations despite double-digit EPS growth through to 2026, on Barclays estimates. Siemens Healthineers trades on more than 19 times.

The best explanation for the share price reaction is that Philips is suffering from sticky negative sentiment, a malady that can afflict companies that have severely spooked the market in recent history.

Curing it requires not just solving one problem, no matter how major. It requires solving all of them. That’s something that GSK, reporting on Wednesday, will be acutely aware of. Following the resolution of the Zantac heartburn medicine legal overhang, analysts are now fretting over the strength of its vaccine sales.

Traumatised investors require a long period of peace and quiet to recover their composure. Philips cannot afford another jolt to their nerves.

camilla.palladino@ft.com

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

相关话题

前劳工统计局局长:特朗普对数据的攻击将造成持久伤害

可靠的政府统计数据是美国经济的基石之一。

印度的俄罗斯石油难题

面对特朗普的施压,莫迪要么接受美国的关税,要么从俄罗斯转向其他供应国,要么尝试与特朗普达成某种妥协。

梅德韦杰夫:从自由派希望到核威胁的漫长转变

这位俄罗斯前总统在社交媒体上公开挑衅特朗普。他已从俄罗斯自由派和白宫决策者眼中的白衣骑士,变成了莫斯科的“核战争狂人”。

数千公司董事在工党税改后离开英国

FT的分析发现,从去年10月到上月,有3790名公司董事报告离开英国,阿联酋成为首选目的地。

局长遭解雇前,美国劳工统计局就已然陷入困境

经费和人员削减阻碍了美国劳工统计局汇总重要报告的能力。

FT社评:特朗普对经济数据的攻击产生寒蝉效应

特朗普解雇美国劳工统计局局长会破坏关键国家统计数据的公信力。
设置字号×
最小
较小
默认
较大
最大
分享×